Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency

RegulatoryPluvictoCurium rival drug candidatePositive

AI Analysis

Summary

Curium is preparing for FDA review of its radiopharma drug candidate to compete with Novartis' blockbuster Pluvicto, positioning supply chain resilience as a competitive advantage.

Outcome Details

FDA review of Curium's radiopharma drug candidate in talks

Importance:5/10

Sentiment:

0.30

radiopharmaFDA reviewsupply chaincompetitionPluvicto

Related Companies

$NVS

Read the original article

Published by BioSpace on August 25, 2026 4:01 AM

Read Original